Navigation Links
Blocking common gateway to inflammation suppresses cancer
Date:6/13/2011

There is an intimate and complex relationship between inflammation and cancer; and it is well established that tumors secrete many different chemicals that attract host cells which drive inflammation and help to support tumor growth. Now, a new study published by Cell Press in the June issue of the journal Cancer Cell identifies a single protein that is required for trafficking of immune cells involved in inflammation. The research opens up new avenues for therapeutics that can indirectly suppress malignancy by disrupting the inflammatory response.

"Tumors induce inflammatory responses that stimulate tumor survival and progression. Therefore, targeting tumor inflammation could provide substantial therapeutic benefit to most, if not all, cancer patients," says senior study author, Dr. Judith A. Varner from the University of California, San Diego. "However, effective suppression of tumor inflammation requires identification and targeting of mechanisms that are common to the many diverse inflammatory pathways that are activated during tumor growth."

In their study, Dr. Varner and colleagues investigated the mechanisms that control tumor growth and inflammation by looking at molecular signals that are commonly activated by multiple diverse tumor-derived chemical signals. The researchers made the unexpected discovery that a single enzyme called PI3Kinase gamma served as a convergent point for a wide range of signaling pathways that controlled both tumor inflammation and progression.

A variety of experimental approaches with mouse and human cells demonstrated that disrupting PI3Kinase gamma prevented invasion of inflammatory cells into the tumor. Tumors developed more slowly and metastasis was suppressed in mice lacking PI3Kinase gamma even though cancer cells did not express PI3Kinase gamma and inhibitors had no direct effect on the tumor cells. The PI3Kinase gamma inhibitors indirectly interfered with the progression of cancer by preventing inflammation. Importantly, because the inhibitors do not directly influence tumor cells, it is not likely that they will develop resistance to PI3Kinase gamma inhibitors.

"Our studies show that PI3Kinase gamma is an excellent target for cancer therapeutics, as this enzyme is primarily expressed in specific immune cells and is a gatekeeper of tumor inflammation and tumor progression," concludes Dr. Varner. "We found that PI3Kinase gamma inhibitors strongly suppressed tumor growth and progression in mice without apparent side effects. Thus, selective inhibitors of PI3Kinase gamma could serve as relatively nontoxic therapeutics to suppress tumor malignancy by blocking diverse pathways promoting tumor inflammation."


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related biology news :

1. Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection
2. Blocking cell movement for cancer, MS treatment
3. Blocking cancer in its path: New cellular defect discovered
4. How blocking the Programmed Death 1 protein may treat or prevent sepsis and severe infection
5. Cranberry juice shows promise blocking Staph infections
6. Tiny RNA molecules control labor, may be key to blocking premature birth
7. Blocking the critical structure that lets cancer cells move -- their feet
8. Blocking rogue gene could stop the spread of most cancers
9. Blocking crucial molecule could help treat multiple sclerosis, Jefferson neuroscientists say
10. Study provides insight on a common heart rhythm disorder
11. Researchers identify Achilles heel of common childhood tumor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
Breaking Biology Technology: